IDH1 and acute myeloid leukemia: Given this patient’s exceptional response and the long duration of CR and CR/CRh (complete remission with partial hematologic recovery) observed in large cohorts of R/R AML patients treated with single agent olutasidenib, the future holds promise for the development novel regimens that may induce treatment-free remission in R/R and even frontline IDH1 mutated AML settings, by incorporating olutasidenib into combination regimens.